Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
89.86 EUR | +0.38% | +0.79% | +0.11% |
May. 27 | Sanofi Gets US FDA’s Priority Review for Expanded Use of Blood Cancer Drug Sarclisa | MT |
May. 27 | Sanofi: FDA grants priority review in myeloma | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.11% | 121B | |
+38.51% | 727B | |
+31.74% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.44% | 205B | |
-5.97% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- SAN Stock
- News Sanofi
- Bank of America, BNP Set to Win Lead Roles on Sanofi's Consumer-Healthcare Spin Off